Skip to main content
Top
Published in: Virology Journal 1/2023

Open Access 01-12-2023 | Vaccination | Research

Safety and immunogenicity of inactivated Rift Valley Fever Smithburn viral vaccine in sheep

Authors: Matome Selina Matsiela, Leeann Naicker, Thandeka Khoza, Nobalanda Mokoena

Published in: Virology Journal | Issue 1/2023

Login to get access

Abstract

Background

The live-attenuated Rift Valley Fever Smithburn (SB) vaccine is one of the oldest products widely used in ruminants for control of RVF infections. Vaccinations with RVF Smithburn result in residual pathogenic effect and is limited for use in non-pregnant animals. Commercially available RVFV inactivated vaccines are considered safer options to control the disease. These products are prepared from virulent RVFV isolates and present occupational safety concerns. This research study evaluates the ability of an inactivated SB vaccine strain to elicit neutralising antibody response in sheep.

Methods

The RVF Smithburn vaccine was inactivated with binary ethylenimine at 37 °C. Inactivated RVFV cultures were adjuvanted with Montande™ Gel-01 and aluminium hydroxide (Al (OH)3) gel for immunogenicity and safety determination in sheep. The commercial RVF inactivated vaccine and a placebo were included as positive and negative control groups, respectively.

Results

Inactivated RVFV vaccine formulations were safe with all animals showing no clinical signs of RVFV infection and temperature reactions following prime-boost injections. The aluminium hydroxide formulated vaccine induced an immune response as early as 14 days post primary vaccination with neutralising antibody titre of 1:20 and a peak antibody titre of 1:83 was reached on day 56. A similar trend was observed in the animal group vaccinated with the commercial inactivated RVF vaccine obtaining the highest antibody titre of 1:128 on day 56. The neutralizing antibody levels remained within a threshold for the duration of the study. Merino sheep vaccinated with Montanide™ Gel-01-Smithburn were characterised with overall lower immune response when compared to aluminium hydroxide vaccine emulsions.

Conclusions

These finding suggests that the inactivated RVF Smithburn vaccine strain adjuvanted with aluminium-hydroxide can be used an alternative to the products prepared from virulent RVFV isolates for protection of ruminants against the disease. The vaccine can further be evaluated for safety in pregnant ewes.
Literature
3.
go back to reference Swanepoel R. Rift Valley fever. In: Coetzer JAW, Tustin RC, editors. Infectious diseases of livestock. Cape Town: Oxford University Press; 2004. Swanepoel R. Rift Valley fever. In: Coetzer JAW, Tustin RC, editors. Infectious diseases of livestock. Cape Town: Oxford University Press; 2004.
4.
go back to reference Ikegami T. Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate. Expert Rev Vaccines. 2017;16(6):601–11.CrossRefPubMedPubMedCentral Ikegami T. Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate. Expert Rev Vaccines. 2017;16(6):601–11.CrossRefPubMedPubMedCentral
5.
go back to reference Daubney R, Hudson J, Garnham P. Enzootic hepatitis or Rift Valley fever. An undescribed virus disease of sheep cattle and man from East Africa. J Pathol Bacteriol. 1931;34(4):545–79.CrossRef Daubney R, Hudson J, Garnham P. Enzootic hepatitis or Rift Valley fever. An undescribed virus disease of sheep cattle and man from East Africa. J Pathol Bacteriol. 1931;34(4):545–79.CrossRef
6.
go back to reference Pepin M, et al. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res. 2010;41(6):61.CrossRefPubMedPubMedCentral Pepin M, et al. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res. 2010;41(6):61.CrossRefPubMedPubMedCentral
7.
go back to reference Grossi-Soyster EN, LaBeaud AD. Rift Valley fever: important considerations for risk mitigation and future outbreaks. Trop Med Infect Dis. 2020;5(2):89.CrossRefPubMedPubMedCentral Grossi-Soyster EN, LaBeaud AD. Rift Valley fever: important considerations for risk mitigation and future outbreaks. Trop Med Infect Dis. 2020;5(2):89.CrossRefPubMedPubMedCentral
10.
go back to reference Morrill J, et al. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine. 1991;9(1):35–41.CrossRefPubMed Morrill J, et al. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine. 1991;9(1):35–41.CrossRefPubMed
11.
go back to reference Botros B, et al. Adverse response of non-indigenous cattle of European breeds to live-attenuated Smithburn Rift Valley fever vaccine. J Med Virol. 2006;78(6):787–91.CrossRefPubMed Botros B, et al. Adverse response of non-indigenous cattle of European breeds to live-attenuated Smithburn Rift Valley fever vaccine. J Med Virol. 2006;78(6):787–91.CrossRefPubMed
12.
go back to reference Smithburn K. Rift Valley fever: the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol. 1949;30(1):1.PubMedPubMedCentral Smithburn K. Rift Valley fever: the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol. 1949;30(1):1.PubMedPubMedCentral
13.
go back to reference Boumart Z, et al. Safety and immunogenicity of the Rift Valley fever arMP-12 ΔNSm21/384 candidate vaccine in pregnant ewes. Vaccine: X. 2020;6:100070.PubMed Boumart Z, et al. Safety and immunogenicity of the Rift Valley fever arMP-12 ΔNSm21/384 candidate vaccine in pregnant ewes. Vaccine: X. 2020;6:100070.PubMed
14.
15.
go back to reference Monath TP, et al. Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile. Vaccine: X. 2020;5:100060.PubMed Monath TP, et al. Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile. Vaccine: X. 2020;5:100060.PubMed
17.
go back to reference Alhaj M. Safety and efficacy profile of commercial veterinary vaccines against Rift Valley fever: a review study. J Immunol Re. 2016;2016:7346294. Alhaj M. Safety and efficacy profile of commercial veterinary vaccines against Rift Valley fever: a review study. J Immunol Re. 2016;2016:7346294.
18.
go back to reference Matsiela MS, et al. Improved safety profile of inactivated Neethling strain of the lumpy skin disease vaccine. Vaccine: X. 2022;12:100209.PubMed Matsiela MS, et al. Improved safety profile of inactivated Neethling strain of the lumpy skin disease vaccine. Vaccine: X. 2022;12:100209.PubMed
19.
20.
21.
go back to reference Dungu B, Lubisi BA, Ikegami T. Rift Valley fever vaccines: current and future needs. Curr Opin Virol. 2018;29:8–15.CrossRefPubMed Dungu B, Lubisi BA, Ikegami T. Rift Valley fever vaccines: current and future needs. Curr Opin Virol. 2018;29:8–15.CrossRefPubMed
22.
go back to reference Barnard B, Botha M. An inactivated rift valley fever vaccine. J S Afr Vet Assoc. 1977;48(1):45–8.PubMed Barnard B, Botha M. An inactivated rift valley fever vaccine. J S Afr Vet Assoc. 1977;48(1):45–8.PubMed
24.
go back to reference Anderson B, et al. Enumeration of bacteriophage particles: comparative analysis of the traditional plaque assay and real-time QPCR-and nanosight-based assays. Bacteriophage. 2011;1(2):86–93.CrossRefPubMedPubMedCentral Anderson B, et al. Enumeration of bacteriophage particles: comparative analysis of the traditional plaque assay and real-time QPCR-and nanosight-based assays. Bacteriophage. 2011;1(2):86–93.CrossRefPubMedPubMedCentral
25.
go back to reference Bahnemann H. Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Adv Virol. 1975;47(1):47–56. Bahnemann H. Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Adv Virol. 1975;47(1):47–56.
26.
go back to reference Moetlhoa B, et al. Application of a real-time cell analysis system in the process development and quantification of Rift Valley fever virus clone 13. Access Microbiol. 2021;3(3):000191.CrossRefPubMed Moetlhoa B, et al. Application of a real-time cell analysis system in the process development and quantification of Rift Valley fever virus clone 13. Access Microbiol. 2021;3(3):000191.CrossRefPubMed
27.
go back to reference Ellis CE, et al. Validation of an ELISA for the concurrent detection of total antibodies (IgM and IgG) to Rift Valley fever virus. Onderstepoort J Vet Res. 2014;81(1):1–6.CrossRef Ellis CE, et al. Validation of an ELISA for the concurrent detection of total antibodies (IgM and IgG) to Rift Valley fever virus. Onderstepoort J Vet Res. 2014;81(1):1–6.CrossRef
28.
go back to reference Frey HR, Liess B. Vermehrungskinetik und Verwendbarkeit eines stark zytopathogenen VD-MD-Virusstammes für diagnostische Untersuchungen mit der Mikrotiter-Methode. Zentralbl Veterinarmed B. 1971;18(1):61–71.CrossRefPubMed Frey HR, Liess B. Vermehrungskinetik und Verwendbarkeit eines stark zytopathogenen VD-MD-Virusstammes für diagnostische Untersuchungen mit der Mikrotiter-Methode. Zentralbl Veterinarmed B. 1971;18(1):61–71.CrossRefPubMed
29.
go back to reference Muench HR. A simple method of estimating 50 per cent end points. Am J Hyg. 1938;27:493–7. Muench HR. A simple method of estimating 50 per cent end points. Am J Hyg. 1938;27:493–7.
30.
go back to reference Smith DR, et al. Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates. PLoS Negl Trop Dis. 2018;12(5):e0006474.CrossRefPubMedPubMedCentral Smith DR, et al. Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates. PLoS Negl Trop Dis. 2018;12(5):e0006474.CrossRefPubMedPubMedCentral
31.
go back to reference Al-Olayan EM et al (2016) An alternative inactivant for Rift Valley Fever virus using cobra venom-derived L-amino oxidase, which is related to its immune potential. Braz Arch Biol Technol 59 Al-Olayan EM et al (2016) An alternative inactivant for Rift Valley Fever virus using cobra venom-derived L-amino oxidase, which is related to its immune potential. Braz Arch Biol Technol 59
32.
go back to reference Blackburn N, Besselaar T. A study of the effect of chemical inactivants on the epitopes of Rift Valley fever virus glycoproteins using monoclonal antibodies. J Virol Methods. 1991;33(3):367–74.CrossRefPubMed Blackburn N, Besselaar T. A study of the effect of chemical inactivants on the epitopes of Rift Valley fever virus glycoproteins using monoclonal antibodies. J Virol Methods. 1991;33(3):367–74.CrossRefPubMed
33.
go back to reference Magd DMA, et al. Effecacy of Montanide gel inactivated RVF vaccine in comparison with aluminum hydroxide gel inactivated one. Benha Vet Med J. 2014;27(1):239–47. Magd DMA, et al. Effecacy of Montanide gel inactivated RVF vaccine in comparison with aluminum hydroxide gel inactivated one. Benha Vet Med J. 2014;27(1):239–47.
34.
go back to reference Fafetine JM, et al. Cloning and expression of Rift Valley fever virus nucleocapsid (N) protein and evaluation of a N protein based indirect ELISA for the detection of specific IgG and IgM antibodies in domestic ruminants. Vet Microbiol. 2007;121(1–2):29–38.CrossRefPubMed Fafetine JM, et al. Cloning and expression of Rift Valley fever virus nucleocapsid (N) protein and evaluation of a N protein based indirect ELISA for the detection of specific IgG and IgM antibodies in domestic ruminants. Vet Microbiol. 2007;121(1–2):29–38.CrossRefPubMed
35.
go back to reference Wallace DB, et al. Protection of cattle elicited using a bivalent lumpy skin disease virus-vectored recombinant Rift Valley fever vaccine. Front Vet Sci. 2020;7:256.CrossRefPubMedPubMedCentral Wallace DB, et al. Protection of cattle elicited using a bivalent lumpy skin disease virus-vectored recombinant Rift Valley fever vaccine. Front Vet Sci. 2020;7:256.CrossRefPubMedPubMedCentral
36.
go back to reference Ronchi GF, et al. Immunogenicity and safety studies of an inactivated vaccine against Rift Valley fever. Acta Trop. 2022;232:106498.CrossRefPubMed Ronchi GF, et al. Immunogenicity and safety studies of an inactivated vaccine against Rift Valley fever. Acta Trop. 2022;232:106498.CrossRefPubMed
37.
38.
go back to reference El Bakkouri K, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol. 2011;186(2):1022–31.CrossRefPubMed El Bakkouri K, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol. 2011;186(2):1022–31.CrossRefPubMed
39.
go back to reference Jegerlehner A, et al. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol. 2004;172(9):5598–605.CrossRefPubMed Jegerlehner A, et al. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol. 2004;172(9):5598–605.CrossRefPubMed
40.
go back to reference Carragher DM, et al. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol. 2008;181(6):4168–76.CrossRefPubMed Carragher DM, et al. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol. 2008;181(6):4168–76.CrossRefPubMed
Metadata
Title
Safety and immunogenicity of inactivated Rift Valley Fever Smithburn viral vaccine in sheep
Authors
Matome Selina Matsiela
Leeann Naicker
Thandeka Khoza
Nobalanda Mokoena
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Vaccination
Published in
Virology Journal / Issue 1/2023
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-02180-2

Other articles of this Issue 1/2023

Virology Journal 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.